Developer docs
API playgroundTry for free, no card

Search company profiles

IMPLEXIS LTD

Full company profile

uuid02byeeh

Namestring
IMPLEXIS LTD
Legal namestring
Implexis Ltd
Websiteurl
implexis.ai
Company typeenum
Private
Founded yearint
2025
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug formulation software, pharmaceutical AI platform, formulation development automation, excipients optimization software, pharma R&D software
Industry1 code
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Pharmaceutical Formulation Development Software
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform Software Services
TypeSubscription Recurring
Description

SaaS-based access to proprietary formulation development platform. The company appears to offer software services to pharmaceutical companies for drug formulation development, likely through subscription or usage-based licensing.

implexis.ai
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Implexis Ltd sells a proprietary SaaS platform that automates drug formulation development for pharmaceutical companies. Users create and manage formulation experiments through the platform, configure excipients and constraints, define search spaces, upload pre-defined experimental data, and run multi-objective or single-objective optimization models to discover optimal formulations faster than traditional trial-and-error methods.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced time-to-market for drug formulations
+2 more records
Product overview1 text field

Implexis is a formulation development platform comprising a proprietary core platform and multiple integrated modules. The platform is designed to accelerate drug formulation development through automation. The product portfolio includes the core Implexis Platform, a Dashboard module for monitoring experiments, an Experiments module for managing formulation development workflows (covering basic information, excipients configuration, constraints and optimization settings), and a Settings module for platform administration. Users can configure search space parameters, define materials and constraints, upload pre-defined experimental data, and select between Multiple Objectives or Single Objective optimization models.

Product and service1 record
1Implexis Platform
CategoryPharmaceutical Formulation Development Software
Description

A proprietary SaaS platform that automates drug formulation development for pharmaceutical and biotech companies. Users configure formulation experiments, set excipients and constraints, define search spaces, upload pre-defined experimental data, and run multi-objective or single-objective optimization models to reduce time-to-market and minimize experimental costs.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Certara offers drug development software including Simcyp for PBPK and formulation prediction, widely used by pharmaceutical companies. It is a direct competitor in the pharmaceutical formulation modeling and drug development software market.

TypeEmerging player
Description

Benchling offers a cloud-based R&D platform for life sciences including ELN, registration, and workflow management used by pharma and biotech. Comparable as a SaaS platform for pharmaceutical scientists, but broader in scope than Implexis' formulation-specific tooling.

TypeDirect peer
Description

Schrödinger provides computational chemistry and physics-based simulation software used by pharma for molecular design, including formulation and materials modeling. It is the most established AI/physics platform in drug discovery and directly competes for the same R&D budget that Implexis targets in formulation development.

TypeEmerging player
Description

Insilico Medicine applies AI to pharmaceutical R&D across drug discovery and development. Comparable as an AI-native life sciences platform targeting pharma, but with broader drug discovery focus rather than formulation specialization.

TypeEmerging player
Description

TetraScience provides a data cloud platform for scientific R&D data in life sciences, including pharma lab data pipelines. Comparable in providing SaaS infrastructure for pharmaceutical R&D workflows, but focused on data layer rather than formulation optimization specifically.

TypeEmerging player
Description

Dotmatics provides an R&D informatics platform for scientific data management and workflow automation across pharma discovery and development. It is comparable in serving pharmaceutical scientists with software that structures experimental workflows, though broader than Implexis' formulation focus.

TypeDirect peer
Description

OpenEye (now part of Cadence) provides molecular modeling and cheminformatics software widely used in pharma R&D including formulation-related property prediction. Comparable to Implexis in offering computational tools for pharmaceutical scientists.

TypeDirect peer
Description

Simulations Plus provides modeling and simulation software for pharmaceutical R&D, including GastroPlus for oral absorption and formulation support. It is a direct competitor serving pharmaceutical formulation scientists with predictive software.

TypeDirect peer
Description

ACD/Labs offers analytical and formulation informatics software used by pharmaceutical chemists for property prediction and formulation decision support. It is a direct peer providing software tools specifically targeting pharmaceutical formulation workflows.

TypeBroad incumbent
Description

BIOVIA is Dassault Systèmes' enterprise scientific software suite covering molecular modeling, lab informatics, and formulation workflows for large pharma. It is a broad incumbent offering overlapping capabilities versus Implexis but as part of a much larger enterprise portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IMPLEXIS LTD

Pharmaceutical Formulation Development Softwareimplexis.ai

IMPLEXIS LTD firmographics

Firmographics
Name
IMPLEXIS LTD
Legal name
Implexis Ltd
Website
https://implexis.ai
Company type
Private
Founded year
2025
Operating status
Operating
Ownership category
akta.pro rank

IMPLEXIS LTD industry classification

Industry
Product category
Pharmaceutical Formulation Development Software
NAICS
Software Publishers (513210)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Drug formulation software
  • Pharmaceutical AI platform
  • Formulation development automation
  • Excipients optimization software
  • Pharma R&D software

Where IMPLEXIS LTD is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

IMPLEXIS LTD business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Platform Software Services: SaaS-based access to proprietary formulation development platform. The company appears to offer software services to pharmaceutical companies for drug formulation development, likely through subscription or usage-based licensing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

IMPLEXIS LTD product offering

Product offering

Core offering

Implexis Ltd sells a proprietary SaaS platform that automates drug formulation development for pharmaceutical companies. Users create and manage formulation experiments through the platform, configure excipients and constraints, define search spaces, upload pre-defined experimental data, and run multi-objective or single-objective optimization models to discover optimal formulations faster than traditional trial-and-error methods.

Product overview

Implexis is a formulation development platform comprising a proprietary core platform and multiple integrated modules. The platform is designed to accelerate drug formulation development through automation. The product portfolio includes the core Implexis Platform, a Dashboard module for monitoring experiments, an Experiments module for managing formulation development workflows (covering basic information, excipients configuration, constraints and optimization settings), and a Settings module for platform administration. Users can configure search space parameters, define materials and constraints, upload pre-defined experimental data, and select between Multiple Objectives or Single Objective optimization models.

Differentiator

Problem solved

Functional benefit

Products and services

  • Implexis Platform A proprietary SaaS platform that automates drug formulation development for pharmaceutical and biotech companies. Users configure formulation experiments, set excipients and constraints, define search spaces, upload pre-defined experimental data, and run multi-objective or single-objective optimization models to reduce time-to-market and minimize experimental costs.

Quantifiable outcome

  • Reduced time-to-market for drug formulations
  • +2 more outcomes

Companies that use IMPLEXIS LTD

Customer profile

Segments1 record

Ideal customer profiles1 record

IMPLEXIS LTD technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

IMPLEXIS LTD partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights2 records

IMPLEXIS LTD competitors and assessment

Company assessment

Direct peers

  • Certara: Certara offers drug development software including Simcyp for PBPK and formulation prediction, widely used by pharmaceutical companies. It is a direct competitor in the pharmaceutical formulation modeling and drug development software market.
  • Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software used by pharma for molecular design, including formulation and materials modeling. It is the most established AI/physics platform in drug discovery and directly competes for the same R&D budget that Implexis targets in formulation development.
  • OpenEye Scientific: OpenEye (now part of Cadence) provides molecular modeling and cheminformatics software widely used in pharma R&D including formulation-related property prediction. Comparable to Implexis in offering computational tools for pharmaceutical scientists.
  • Simulations Plus: Simulations Plus provides modeling and simulation software for pharmaceutical R&D, including GastroPlus for oral absorption and formulation support. It is a direct competitor serving pharmaceutical formulation scientists with predictive software.
  • ACD/Labs: ACD/Labs offers analytical and formulation informatics software used by pharmaceutical chemists for property prediction and formulation decision support. It is a direct peer providing software tools specifically targeting pharmaceutical formulation workflows.

Emerging players

  • Benchling: Benchling offers a cloud-based R&D platform for life sciences including ELN, registration, and workflow management used by pharma and biotech. Comparable as a SaaS platform for pharmaceutical scientists, but broader in scope than Implexis' formulation-specific tooling.
  • Insilico Medicine: Insilico Medicine applies AI to pharmaceutical R&D across drug discovery and development. Comparable as an AI-native life sciences platform targeting pharma, but with broader drug discovery focus rather than formulation specialization.
  • TetraScience: TetraScience provides a data cloud platform for scientific R&D data in life sciences, including pharma lab data pipelines. Comparable in providing SaaS infrastructure for pharmaceutical R&D workflows, but focused on data layer rather than formulation optimization specifically.
  • Dotmatics: Dotmatics provides an R&D informatics platform for scientific data management and workflow automation across pharma discovery and development. It is comparable in serving pharmaceutical scientists with software that structures experimental workflows, though broader than Implexis' formulation focus.

Broad incumbents

  • Dassault Systèmes BIOVIA: BIOVIA is Dassault Systèmes' enterprise scientific software suite covering molecular modeling, lab informatics, and formulation workflows for large pharma. It is a broad incumbent offering overlapping capabilities versus Implexis but as part of a much larger enterprise portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

IMPLEXIS LTD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IMPLEXIS LTD leadership team

Management profile

Number of profiles

Profiles5 records

IMPLEXIS LTD funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IMPLEXIS LTD M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMPLEXIS LTD

What does IMPLEXIS LTD do?

Implexis Ltd sells a proprietary SaaS platform that automates drug formulation development for pharmaceutical companies. Users create and manage formulation experiments through the platform, configure excipients and constraints, define search spaces, upload pre-defined experimental data, and run multi-objective or single-objective optimization models to discover optimal formulations faster than traditional trial-and-error methods.

Is IMPLEXIS LTD a public or private company?

IMPLEXIS LTD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was IMPLEXIS LTD founded?

IMPLEXIS LTD was founded in 2025.

Where is IMPLEXIS LTD based?

IMPLEXIS LTD is headquartered in London, United Kingdom, in the Europe region.

How does IMPLEXIS LTD make money?

One revenue line is on record: platform Software Services.

Who are IMPLEXIS LTD's main competitors?

Direct peers on record are Certara, Schrödinger, OpenEye Scientific, Simulations Plus and ACD/Labs. Emerging players are Benchling, Insilico Medicine, TetraScience and Dotmatics. Dassault Systèmes BIOVIA is listed as a broad incumbent.

Does IMPLEXIS LTD have an API?

No public API is recorded for IMPLEXIS LTD.

What industry is IMPLEXIS LTD in?

IMPLEXIS LTD's product category is Pharmaceutical Formulation Development Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales